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Background. Studies on the association between the long-
term use of aspirin and other analgesic and nonsteroidal anti-
inflammatory drugs (NSAIDs) and end-stage renal disease
(ESRD) have given conflicting results. In order to examine this
association, a case-control study with incident cases of ESRD
was carried out.
Methods. The cases were all patients entering the local dial-
ysis program because of ESRD in the study area between June
1, 1995 and November 30, 1997. They were classified according
to the underlying disease, which had presumably led them to
ESRD. Controls were patients admitted to the same hospitals
from where the cases arose, also matched by age and sex. Odds
ratios were calculated using a conditional logistic model, in-
cluding potential confounding factors, both for the whole study
population and for the various underlying diseases.
Results. Five hundred and eighty-three cases and 1190 con-
trols were included in the analysis. Long-term use of any anal-
gesic was associated with an overall odds ratio of 1.22 (95%
CI, 0.89–1.66). For specific groups of drugs, the risks were 1.56
(1.05–2.30) for aspirin, 1.03 (0.60–1.76) for pyrazolones, 0.80
(0.39–1.63) for paracetamol, and 0.94 (0.57–1.56) for nonaspirin
NSAIDs. The risk of ESRD associated with aspirin was related
to the cumulated dose and duration of use, and it was particu-
larly high among the subset of patients with vascular nephropa-
thy as underlying disease [2.35 (1.17–4.72)].
Conclusion. Our data indicate that long-term use of
nonaspirin analgesic drugs and NSAIDs is not associated with
an increased risk of ESRD. However, the chronic use of aspirin
may increase the risk of ESRD.
There is experimental and clinical evidence link-
ing long-term use of analgesics and nonsteroidal anti-
inflammmatory drugs (NSAIDs) with chronic kidney
disease [1, 2]. Four cohort studies and six case-control
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studies have been published that have yielded conflict-
ing results [3–14]. The strongest evidence pertain to
phenacetin-containing drugs, but the epidemiologic ev-
idence concerning analgesics other than phenacetin and
their relation with end-stage renal disease (ESRD) or
with chronic renal disease (CRD) is inconclusive. Dif-
ficulties in interpreting the results of the epidemiologic
studies include lack of dose-response and sparse data,
besides methodologic limitations. Among the analgesics,
acetaminophen has generated great concern because it
is the main metabolite of phenacetin. Evidence of the
nephrotoxicity of chronic use of NSAIDs is also scarce
[10, 12]. However, high acute doses of NSAIDs have been
implicated as causes of acute renal failure [15]. Besides,
there is little information on the association between the
chronic use of these drugs and the risk of specific pat-
terns of kidney disease other than interstitial disease [10,
12, 14, 16].
In order to estimate the risk of ESRD associated with
the chronic use of analgesics and NSAIDs, we conducted
a case-control study with incident cases of ESRD.
METHODS
Patients
All patients entering into a dialysis program because
of ESRD between June 1, 1995 and November 30, 1997
at all the dialysis centers of the Metropolitan Area of
Barcelona were potential cases. Patients with serious gen-
eral condition or with physical impairment such as deaf-
ness or blindness, those with mental disability, or illiterate
(all these conditions impede interview), those who had
received a kidney transplant, and those nonresidents in
the study area were excluded.
For each case, two hospital controls, matched to the
case by age (within ±5 years), sex, and hospital where
the case was first diagnosed, were randomly selected
from hospital admission lists, including acute conditions
not known to be related with the use of analgesics or
NSAIDs, including aspirin used as analgesic/NSAID or
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as cardiovascular prophylaxis. Patients admitted because
of trauma not alcohol or osteoporosis related, appendici-
tis, nonpainful inguinal hernia, prostatic adenoma, and
cataracts, were the most frequent selected diagnoses in
the control group.
Data collection
After obtaining informed consent, trained nurses inter-
viewed cases and controls using a standardized question-
naire which included a “life history” review of ailments
that might lead to intake of analgesic or NSAIDs (e.g.,
headache), as well as a review of an extensive list of anal-
gesic drugs and NSAIDs product names in use for the
last 20 years (shown as color photographic pictures). In
an attempt to minimize the tendencies of denial or under-
reporting of use, the questions were phrased in a nonjudg-
mental tone. In addition to a detailed drug history, data
collection included demographic information such as age,
sex, number of years of education, detailed medical in-
formation including dates and other information on the
first diagnosis of renal disease, first appearance of signs
or symptoms of renal disease, and a history of major ill-
nesses, occupational exposures, smoking, and alcohol and
caffeine consumption.
Through a separate mechanism, one of us (M.J.M.) ab-
stracted the medical record from the hospital where the
renal failure was diagnosed. This information was used
to classify the cases of ESRD according to their previous
renal disease with a set of clinical, biochemical, and/or
histologic criteria, which are used in everyday clini-
cal practice (available at http://www.icf.uab.es/protocols).
Patients were classified in seven diagnostic categories: in-
terstitial nephritis, glomerulonephritis, cystic kidney dis-
ease, diabetic nephropathy, vascular nephropathy, mixed
(i.e., impairment both of glomerulus and interstitium),
and unknown. This last category included those patients
who could not be classified in the other categories.
Definition of exposure
Patients were classified as “users” if there were any
data suggesting that they had used any analgesic or
NSAID product daily or every other day for 30 days
or longer at any time before the date of the first diag-
nosis of kidney disease. This index date was established
by two investigators blinded to drug use from informa-
tion provided by patients and from the medical records.
The index date for the controls was the same as for their
matched cases. Total exposure to any given analgesic
(aspirin, pyrazolones, acetaminophen, NSAIDs) or com-
bination of analgesics was recorded both as amount (in
equivalents of defined daily doses, DDDs, as established
by the WHO Collaborating Center for Drug Statistics
[17]) and duration. In order to evaluate potential infor-
mation bias, an additional analysis was performed taking
into account a different exposure definition as any use of
the drugs of interest for six months or longer. In order to
evaluate potential confounding by protopathic bias, an-
other analysis was done where exposures during the two
years immediately before the index date were ignored.
Data analysis
Estimates of the odds ratio (OR) and associated 95%
CIs were calculated using conditional or unconditional
logistic models. The following potential confounding fac-
tors were included in the models: previous history of
smoking, hypertension, arteriopathy, diabetes, kidney
stones, and gout, all before the diagnosis of renal disease.
For the analysis of the association between previous use
of aspirin and vascular nephropathy, a history of coronary
heart disease (CHD) or stroke was added to the model
as an independent variable. Additional variables for use,
duration (cumulated number of days of exposure to anal-
gesics or NSAID drugs), and cumulated DDDs were in-
cluded when OR estimates for the different categories
were calculated. The different categories were selected
in order to differentiate mild, moderate, and heavy users.
For each analysis, patients were included only if complete
information was available on all the variables included in
the particular model.
RESULTS
During the study period, 826 patients entered a dialysis
program because of ESRD in the metropolitan Area of
Barcelona. The incidence was 113.8 per million inhabi-
tants and per year. Of these 826 patients, 227 could not
be interviewed due to physical impairment (75, 33%),
mental disability (54, 24%), illiteracy (43, 19%), refusal
of interview (30, 13%), or death before the interview (25,
11%). Out of 1751 controls approached, 551 could not be
interviewed due to physical impairment (237, 43%), men-
tal disability (176, 32%), refusal of interview (83, 15%),
or illiteracy (55, 10%). This left 599 cases (67.8% male)
and 1200 controls who were interviewed. One hundred
cases (16.7%) were 14 to 45 years old at the time of inter-
view, 145 (24, 2%) were 46 to 60 years old, 270 (45, 1%)
were 61 to 75 years old, and 84 (14%) were over 75 years.
Age and sex distribution (which were matched) did not
differ from those among controls. The median age was
64 (min 16, max 89) among cases, and 63 among controls
(min 13, max 91).
After the interview, 16 cases and 10 controls were ex-
cluded from the analysis because information was judged
unreliable by the interviewer, thus leaving 583 cases and
1190 controls. Sixty-three additional cases and their cor-
responding 208 controls had to be excluded from the
analyses performed with conditional models because in-
formation on at least one of the variables included in the
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Table 1. Risk of ESRD associated with the use of analgesics and
NSAIDs, according to the duration of use and the cumulated dosea
Number Number of
of cases controls Odds
(N = 520) (N = 982) ratio 95% CI
Non users 398/520 816/982 1.0 (Reference class)
Users 122/520 166/982 1.22 0.89–1.66
Age of case
<65 male 33/190 45/367 1.00 0.56–1.79
<65 female 13/92 17/173 1.61 0.68–3.82
≥65 male 45/162 54/302 1.73 0.95–3.15
≥65 female 31/76 50/140 1.12 0.62–2.02
Male 78/352 99/669 1.20 0.80–1.80
Female 44/168 67/313 1.18 0.71–1.94
All <65 46/282 62/540 1.18 0.74–1.90
All ≥65 76/238 104/442 1.40 0.92–2.12
Duration
≤1 year 39/517 64/975 0.96 0.61– 1.54
>1–5 years 33/517 46/975 1.30 0.75–2.25
>5 years 47/517 54/975 1.41 0.87–2.27
Cumulated
dose (DDDs)
≤100 37/506 64/946 0.85 0.52–1.39
>100–500 29/506 45/946 1.05 0.60–1.86
>500 42/506 42/946 1.69 0.99–2.88
aBased on 520 cases and 982 controls. For 3 and 14 cases and 7 and 36 controls,
respectively, information on the duration of use or the cumulated dose was lacking.
model was unknown, thus leaving 520 cases and 982 con-
trols for the main analyses.
Out of 599 cases, the records of 587 could be traced out
and abstracted. Of these, 197 (33.6%) were classified as
vascular nephropathy, 100 (17.0%) as glomerulonephri-
tis, 76 (12.9%) as interstitial nephritis, 64 (10.9%) as dia-
betic nephropathy, 51 (8.7%) as cystic kidney disease, 20
(3.4%) as mixed, and 79 (13.5%) as unknown.
In order to explore bias in the selection of controls, the
use of analgesics across the different diagnostic categories
of controls was examined. This was 15.6% among those
with trauma (N = 519), 14.2% among those with surgical
digestive conditions (N = 310), 19.3% among those with
prostate adenoma (N = 176), and 20% among those with
other conditions (N = 185).
ESRD was associated with a previous history of hyper-
tension (186 cases and 154 controls, OR = 3.07, 95%CI,
2.28–4.15), gout (64 cases and 40 controls; OR = 3.61,
95%CI, 2.23–5.84), diabetes (85 cases and 62 controls, OR
= 3.02, 95%CI, 2.01–4.54), kidney stones (107 cases and
147 controls, OR = 1.52, 95%CI, 1.11–2.07), and periph-
eral arteriopathy (20 cases and 11 controls, OR = 3.74,
95%CI, 1.54–9.06). An additional result was a significant
association of ESRD with current or past smoking (320
cases and 557 controls, OR = 1.54, 95%CI, 1.14–2.07).
Chronic use of analgesic drugs or NSAIDs (accord-
ing to the predefined criteria) was reported by 137 cases
(23.5%) and 196 controls (16.5%), thus giving an odds
ratio of 1.22 (95% CI, 0.89–1.66). Table 1 shows the esti-
mates by sex and age of the cases, and according to the to-
tal duration of use and cumulated dose. The main reasons
Table 2. Risk of ESRD associated with specific analgesic drugs and
NSAIDs
Number Number of
of cases controls Odds
Analgesic drug (N = 520) (N = 982) ratio 95% CI
Aspirin 81 94 1.56 1.05–2.30
Pyrazolonesa 34 51 1.03 0.60–1.76
Acetaminophen 18 31 0.80 0.39–1.63
NSAIDsb 37 51 0.94 0.57–1.56
aPyrazolones: amidopyrine (1 case and 2 controls), metamizol (11 cases and
21 controls), phenazone (6 cases and 9 controls), propyphenazone (20 cases and
23 controls).
bNonsteroidal anti-inflammatory drugs: aceclofenac (1 case and 4 controls),
diclofenac (20 cases and 33 controls), ibuprofen (1 case and 2 controls),
indomethacin (9 cases and 7 controls), naproxen (1 case and 1 control),
oxyphenbutazone (2 cases and 5 controls), piroxicam (3 cases and 9 controls),
phenylbutazone (2 cases and 2 controls), tenoxicam (1 control).
for the use of analgesic drugs and NSAIDs were headache
(37% of cases and 34% of controls), musculoskeletal and
joint pain (30% of cases and 32% of controls), and car-
diovascular conditions (for aspirin, 12% of cases and 7%
of controls).
As shown in Table 2, the risk for ESRD associated
with the various categories of analgesics and NSAIDs was
1.56 (95%CI, 1.05–2.30) for aspirin, 1.03 (95%CI, 0.60–
1.76) for pyrazolones, 0.80 (95%CI, 0.39–1.63) for ac-
etaminophen, and 0.94 (95%CI, 0.57–1.56) for nonaspirin
NSAIDs. There were three cases and two controls ex-
posed to salicylamide, giving an overall OR value for sal-
icylates of 1.57 (95%CI, 1.06–2.34). The risk associated
with phenacetin was not estimated because only seven
cases and nine controls had been exposed to it. We did
not find any statistically significant specific association
of ESRD with exposure to caffeine-containing drugs (38
cases and 48 controls, OR = 1.41; 95%CI, 0.86–2.30) or to
analgesic mixtures (12 cases and 18 controls, OR = 1.09;
95%CI, 0.48–2.47).
The risks of ESRD associated with any use of analgesics
and NSAIDs for each diagnostic category are shown in
Table 3. No particular statistically significant associations
were found, except a borderline significant risk of mixed
nephropathy.
When the exposure window was widened to six months
at any time before the first symptom, the OR values
were 1.88 (95%CI, 1.22–2.87) for aspirin, 1.17 (95%CI,
0.61–2.25) for pyrazolones, 0.39 (95%CI, 0.16–0.96) for
acetaminophen, and 1.09 (95%CI, 0.55–2.17) for non-
aspirin NSAIDs. When the use during the two years im-
mediately before the index date was ignored, the cor-
responding risk estimates were 1.57 (95%CI, 1.03–2.38)
for aspirin, 1.05 (95%CI, 0.60–1.85) for pyrazolones, 0.64
(95%CI, 0.29–1.43) for acetaminophen, and 0.98 (95%CI
0.55–1.72) for nonaspirin NSAIDs. The effect of aspirin
was related with the cumulated dose (trend test, P =
0.012) and duration of use (P = 0.012) (see Table 4).
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Table 3. Risk of ESRD associated with the use of analgesics and
NSAIDs, according to the pattern of renal disease
Number of Number of
Diagnostic category exposed exposed Odds
(number of patients)a cases controls ratio 95% CI
Diabetic nephropathy (54) 17 18 3.15 0.48–20.86
Glomerulonephritis (91) 10 28 0.47 0.20–1.13
Interstitial nephritis (66) 14 19 0.80 0.30–2.18
Mixed nephropathy (17) 6 2 10.71 0.94–121.7
Vascular nephropathy (167) 47 58 1.40 0.78–2.52
Cystic kidney disease (49) 8 13 0.98 0.34–2.82
Unknown (65) 15 23 1.43 0.60–3.39
aFor 11 patients the diagnostic group could not be determined because the
clinical record was not available.
Table 4. Risk of ESRD associated to aspirin according to the
duration of use and cumulated dose
Number of Number of
exposed exposed Odds
cases controls ratio 95% CI
Duration
≤1 year 19 23 1.24 0.60–2.57
>1–5 years 21 33 1.37 0.72–2.61
>5 years 37 36 2.07 1.16–3.70
Cumulated dose, DDDs
≤100 25 35 1.15 0.62–2.14
>100–500 24 27 1.75 0.87–3.49
>500 24 26 2.09 1.05–4.17
The risk associated with aspirin for cardiovascular pro-
phylaxis was 1.55 (95%CI, 0.77–3.12), and the risk asso-
ciated with its use in noncardiovascular indications, the
main indication in our study, was 1.55 (95%CI, 0.99–
2.44).
There were 167 cases of ESRD presumably due to
vascular nephropathy. In this subset of patients, the risk
of ESRD associated to chronic use of aspirin was 2.01
(95%CI, 0.98–4.15, based on 166 cases, since one case
could not be included in this analysis due to lack of infor-
mation on past cardiovascular history). Fourteen patients
in the subset of mixed nephropathy presented with a di-
agnosis of vascular nephropathy, and they were, there-
fore, added to those of simple vascular nephropathy. This
mixed category (17 patients) was made mainly of patients
with vascular nephropathy combined with other diag-
noses (14). For these 180 vascular cases, the OR value
was 2.35 (95%CI, 1.17–4.72).
There were 94 cases and 76 controls with a previous
history of diabetes before kidney disease was diagnosed.
Of these, complete information was available on 85 and
71, respectively. The duration of diabetes had been 14.5
years among cases and 8.1 among controls. An uncondi-
tional analysis of these patients controlled by sex, age,
and duration of disease gave an odds ratio estimate of
3.5 (95%CI, 1.09–11.28) for the use of aspirin, which was
related to the duration of aspirin use (OR = 1.19; 95%CI,
1.03–1.37 for each year of use). Similarly, there were 202
cases and 185 controls with a history of hypertension,
with complete information on 186 and 175, respectively.
Among these patients, no significant increase in the risk
of ESRD associated with aspirin use was seen (OR =
1.55, 95%CI, 0.87–2.75).
The association of current or past smoking with
ESRD was present across all diagnostic categories;
among patients with vascular nephropathy it was
1.85 (95%CI, 1.00–3.44), and it was particularly high
among diabetic patients (OR = 4.41; 95%CI, 1.45–
13.38).
DISCUSSION
We did not find any increase of the risk of ESRD in as-
sociation with the use of nonaspirin analgesic drugs and
NSAIDs. The upper limits of the 95% CIs of the risks as-
sociated with pyrazolones, acetaminophen, and NSAIDs
were lower than 2, and no increase in the risks were seen
in relation with the cumulated dose and duration of use.
This suggests that, if an association between chronic use
of these drugs and ESRD exists, its magnitude would be
low. In contrast, we found a moderate increase of the risk
of ESRD associated with the chronic use of aspirin that
was related to the cumulated dose and duration of use,
and which seemed to be present both for cardiovascular
and noncardiovascular aspirin.
The association between chronic consumption of anal-
gesic drugs and chronic renal disease has been examined
at least in four cohort studies [3–7] and in six case-control
studies [8–14]. However, the epidemiologic evidence re-
garding the role of analgesics or NSAIDs is conflicting.
In five of these studies, a moderate increase in the risk
was seen for any analgesic drug use [6, 9, 10, 12, 14]. Ac-
etaminophen has been associated with a risk of chronic
renal failure or ESRD in some studies [7, 9, 10, 13, 14],
but not in others [5, 6, 8]. No association between chronic
consumption of aspirin and impairment of renal function
has been found in four cohort studies [3–7]. However,
three case-control studies have suggested an association
between chronic use of aspirin and chronic renal failure
or ESRD [9, 12, 14], although in another three studies this
association was not seen [8, 10, 13]. NSAIDs have been
found to be associated with a risk of chronic renal failure
or ESRD in two case control studies [11, 13], but not in
two cohort studies in healthy people [5, 6, 7]. Further-
more, the nature of the dose-response relationships, the
patterns of kidney disease caused by analgesics, and the
pathologic mechanisms leading to chronic renal failure
remain unclear [18].
The association of ESRD with aspirin remained sig-
nificant when the minimal duration of exposure was
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widened to a six-month period, and when exposures dur-
ing the two years immediately before the index date were
ignored. The first of these analyses was done in order to
exclude information bias potentially arising from dif-
ferential patients’ awareness of a possible association
between chronic use of medicines and renal disease.
The second one was performed in order to exclude
misclassification of the index day (i.e., the possibil-
ity that the medicines of interest had been taken for
vague symptoms of the disease or for predisposing con-
ditions), before the diagnosis of kidney disease was
made.
Across the different diagnostic categories of ESRD,
the risk associated with aspirin was only significant for
vascular nephropathy, although only when patients with
this condition also combined with other diagnoses were
added. Results of clinical trials with aspirin in secondary
cardiovascular prevention have shown a higher propor-
tion of patients with elevations in serum urea nitrogen,
uric acid, and creatinine [19, 20]. In addition, the results
of a recent cohort study showed a possible but nonsignifi-
cant increase in risk for change in kidney function in par-
ticipants with cardiovascular risk factors who were users
of aspirin [6]. Our subgroup analyses in cases and con-
trols with diabetes or hypertension before the diagnosis
of kidney disease suggest that the risk associated with the
use of aspirin may be especially increased among patients
with diabetes. The risk associated with aspirin was not af-
fected by controlling for age or duration of diabetes, and
it was related with the duration of use of aspirin. How-
ever, residual or unmeasured confounding by indication
cannot be completely excluded. A metanalysis of clinical
trials with focus on renal outcomes may give more light
on this issue.
Finally, we found an association between ESRD and
smoking. The relation between smoking and coronary
heart disease or stroke is well known. Several studies have
indicated that smoking may increase the risk of ESRD in
hypertensive patients [21], and accelerate the progres-
sion to ESRD in type 1 and type 2 diabetic, as well as in
nondiabetic patients [22].
Refusals of interview were low and similar among cases
and controls. It was also reassuring that the distributions
of use of the drugs of interest among controls were gener-
ally similar across the major diagnostic categories. How-
ever, assessment of drug exposure over the whole life
could have led to some degree of exposure misclassifi-
cation due to a possible recall bias in cases as well as
in controls. We tried to minimize it by using a photo-
graphic catalog, which included the main analgesic drugs
and NSAIDs marketed during the last 20 years. The fact
that analgesic use is known as a possible cause of kid-
ney damage could have led to underreporting of its use,
especially among the cases, and could have led to an un-
derestimation of its risk [18].
CONCLUSION
We found that chronic use of aspirin was associated
with a moderate increase in risk of ESRD. This associa-
tion was particularly notable in patients with a previous
history of diabetes, and in those with vascular nephropa-
thy as the underlying disease leading to ESRD. These re-
sults should be taken with caution since they have arisen
from a subgroup analysis, and should be confirmed by
other studies. However, they deserve consideration due
to the high prevalence of diabetes and of the use of as-
pirin in this population, and they should be considered in
the light of the proven cardiovascular effects of aspirin.
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